Market Highlights
Gastrointestinal (GI) drug market involves pharmacological
and non-pharmacological treatment. Different types of gastrointestinal disorder
includes constipation, diverticular diseases, colon polyps, irritable bowel
syndrome, and many more. Many of the GI diseases can be prevented and minimized
by maintaining a healthy lifestyle and balanced diet. The factors like
increasing prevalence of increasing of various different gastrointestinal
disease, increasing elderly population, technological advances are responsible
for driving gastrointestinal market. Whereas unavailability of treatment for
some of gastro intestinal diseases may be responsible for hampering the market
growth.
Americas Market Player for Gastrointestinal Drugs
There are players in global and local gastrointestinal drug
market: AbbVie Inc. (US), AstraZeneca
(UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG
(Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited
(Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi
(France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke
Pharma (US), Valent Pharmaceuticals(US)
Request For Sample Report: https://www.marketresearchfuture.com/sample_request/583
AstraZeneca has entered into an agreement with
gastroenterology specialist Tillotts Pharma for Entocort. Entocort is a
gastroenterology medicine for patients with mild to moderate Crohn’s disease and
ulcerative colitis. The medicine is now available in across 40 countries, the
product sales gained $53 million outside the US in 2014. The agreement shows
that Tillotts will pay AstraZeneca $215 million on completion of the
transaction to acquire the rights to sell and develop Entocort capsules and
formulations outside the US.
Janssen Biotech Inc., the company received FDA approval for
the Remicade medicine which is used to treat pediatric ulcerative colitis in
2011. Since then company has a product for pediatric gasrtrointestinal drugs.
GlaxoSmithKline Plc, has a products Eno available in Latin
America and Asian market. The product is doing extremely well in these regions.
The product is available in various flavor. The product is an antacid. The
product is also available in different forms. Company has vast range of
products in consumers based and in prescription based products. It hold very
strong presence worldwide.
Bayer AG, the company has a wide range of the
gastrointestinal products. One of the product Iberogast is herbal product which
give relief from multiple problems of gastrointestinal system.
Segmentation:
The Segmentation for Americas Gastrointestinal Drug market
is done on the basis of drug category, route of administration, disease type,
and by end users. On the basis of the drug category the market is segmented
into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory,
Antiemetic and others. Further the Acid Neutralizers are sub-segmented into
Antacid, H2 antagonists, Proton Pump Inhibitors and others. On the basis of
route of administration the segments includes oral, parental and rectal. On the
basis of disease type, market is segmented into gastro-esophageal reflux
diseases, inflammatory bowel diseases and others. The inflammatory diseases are
further segmented into two types Crohn’s diseases and ulcerative disease. The
Ulcerative diseases are further sub segmented into ulcerative protitis,
proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive
colitis. The end user segment includes hospital pharmacies, retail pharmacies
and others.
Browse Complete Report: https://www.marketresearchfuture.com/reports/americas-gastrointestinal-drugs-market-583
No comments:
Post a Comment